Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUST: Tazemetostat Rollover Study
2023-510553-41-00Phase 2Completed
- Sponsor
- Epizyme, Inc.
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of tazemetostat in Neoplasm, sponsored by Epizyme, Inc. Primary endpoints: Number of subjects with adverse events related to study drug, Number of subjects with adverse events and 1 more. Started Aug 2016; status: completed.
02
Drugs
tazemetostat
03
Conditions
Neoplasm
Beyond the preview
Go deeper on 2023-510553-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510553-41-00.